HCWB HCW Biologics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1828673 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,487.6%
TTM net income YoY64.7%
TTM EPS YoY162.3%
Revenue 3-yr CAGR32.8%
Net income 3-yr CAGR—
Margins
Gross margin96.6%
Operating margin-104.2%
Net margin-63.4%
FCF margin—
EBITDA margin-96.1%
Returns
ROE-180.3%
ROA-16.8%
ROIC (approx.)-116.5%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets72.8%
Debt / equity0.00x
Current ratio0.07x
Interest coverage-12.39x
Cash quality & payout
Operating cash flow / net income2.71x
Accruals ratio28.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $51,169 | $121,730 | $6.50M | $27,010 | $15,606 | $6,550 | $5,065 | $394,804 |
| Cost of revenue | $27,345 | $229,455 | $11,071 | $21,609 | $12,485 | $5,240 | $4,052 | $315,843 |
| Gross profit | $28,118 | -$93,887 | $6.53M | $5,401 | $3,121 | $1,310 | $1,013 | $78,961 |
| R&D expense | $1.24M | $1.20M | $1.26M | $1.33M | $1.40M | $1.23M | $1.48M | $1.05M |
| SG&A expense | $1.37M | $1.87M | $1.83M | $1.51M | $1.88M | $2.10M | $2.23M | $2.03M |
| Operating income | -$2.59M | -$3.17M | $3.24M | -$4.46M | -$3.29M | -$3.46M | -$1.97M | -$3.15M |
| Interest expense | $141,797 | $100,541 | $109,274 | $212,128 | $127,070 | $228,714 | $255,822 | $260,376 |
| Pretax income | -$3.22M | -$5.22M | $3.80M | $719,232 | -$4.55M | -$1.93M | -$2.20M | — |
| Income tax | $0 | $0 | $330,186 | $0 | — | — | $0 | $0 |
| Net income | -$3.22M | -$5.22M | $3.47M | $719,232 | -$4.55M | -$1.93M | -$2.20M | -$3.37M |
| EBITDA | -$2.47M | -$3.04M | $3.38M | -$4.30M | -$3.12M | -$3.17M | -$1.55M | -$2.46M |
| EPS (basic) | -2.83 | -11.58 | 1.39 | — | -12.09 | -40.72 | -11.80 | — |
| EPS (diluted) | -2.83 | -11.58 | 1.39 | — | -12.09 | -40.72 | -11.80 | — |
| Weighted avg. shares (diluted) | 2.10M | 1.33M | 904,312 | — | 376,678 | 296,686 | 186,149 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $955,458 | $741,324 | $1.23M | $1.95M | $1.10M | $2.44M | $1.11M | $4.67M |
| Short-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Receivables | — | $18,451 | $74,844 | $32,175 | $30,667 | $21,611 | $87,493 | $582,201 |
| Current assets | $1.28M | $1.14M | $1.72M | $2.28M | $1.59M | $2.90M | $1.89M | $5.70M |
| PP&E, net | $18.96M | $20.75M | $20.77M | $20.88M | $22.50M | $22.64M | $22.76M | $22.91M |
| Total assets | $25.13M | $26.77M | $27.34M | $24.52M | $25.45M | $28.91M | $26.29M | $30.24M |
| Current liabilities | $17.61M | $18.65M | $19.96M | $21.06M | $26.86M | $26.85M | $27.14M | $29.63M |
| Short-term debt | $6.83M | $6.56M | $6.58M | $6.81M | $6.81M | $6.42M | $6.23M | $6.31M |
| Long-term debt | — | — | — | $0 | $0 | $367,151 | $7.71M | $7.38M |
| Total debt | — | — | — | $6.81M | $6.81M | $6.79M | $13.94M | $13.69M |
| Total liabilities | $18.30M | $19.34M | $21.58M | $21.76M | $27.55M | $28.96M | $34.85M | $37.01M |
| Shareholders' equity | $6.82M | $7.43M | $5.76M | $2.76M | -$2.11M | -$51,971 | -$8.56M | -$6.77M |
| Net debt | — | — | — | $4.86M | $5.71M | $4.35M | $12.83M | $9.02M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.62M | -$3.97M | -$1.58M | -$3.36M | -$3.24M | -$3.28M | -$3.51M | -$2.83M |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $0 | $113,412 |
| Free cash flow | — | — | — | -$3.36M | -$3.24M | -$3.28M | -$3.51M | -$2.95M |
| Investing cash flow | — | — | — | $0 | $0 | $0 | $0 | -$113,412 |
| Financing cash flow | $2.83M | $3.48M | $851,641 | $4.21M | $1.90M | $4.61M | -$53,103 | $6.62M |
| Depreciation & amortization | $120,072 | $127,095 | $142,049 | $156,940 | $173,905 | $291,916 | $419,010 | $682,507 |
| Stock-based compensation | $364 | $1,220 | $10,019 | $9,182 | $205,492 | $278,307 | $275,642 | $292,071 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.